semaglutide vision A review of more than 30 million FDA adverse event reports examined vision-related safety signals among people using semaglutide, a widely prescribed GLP-1 medication. One formulation showed nearly five times greater Vision loss with GLP-1s: Wegovy

Either the manufacturer can supply or they cant and FDA uses this shortage list to try to inform and to allow for supply outside of the normal approval process, said the former FDA investigations branch director

It doesn't predict what a specific individual will experience with a compounded formulation

doi:10.1186/1471-2393-10-17 [56] Keller U, van der Wal C, Seliger G, et al

doi:10.1155/2014/728038

Daily drops are not forgiving

Eric Nolen-Doerr, MD, an endocrinologist and weight-management specialist at Boston Medical Center and an assistant professor at the Boston University Chobanian & Avedisian School of Medicine